GOG 3025: DUO-O: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Durvalumab (MEDI4736) in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Ad
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
January 18, 2019
End Date
November 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
January 18, 2019
End Date
November 30, 2022